Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.9654
−$0.0071 · -0.73%
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Previous close
$0.9654
−$0.0071 · -0.73%
Regular session · ET · Market data may be delayed.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Day range
Current $0.9654
52-week range
Current $0.9654
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
49
Fair Value
Sentiment
55
Mixed
Risk
85
Extreme Risk
Momentum
27
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Day range
Current $0.9654
52-week range
Current $0.9654
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.01M USD | 607.57K USD | 253.57K USD | 223.21K USD | 1.16M USD |
| Cost of goods sold | 781.7K USD | 384.77K USD | 474.55K USD | 432.37K USD | 850.74K USD |
| Gross profit | 223.78K USD | 222.81K USD | −220.98K USD | −209.16K USD | 309.6K USD |
| Research and development | 2.11M USD | 4.99M USD | 691.77K USD | 525.56K USD | 5.51M USD |
| Selling, general, and administrative | 6.28M USD | 5.02M USD | 4.24M USD | 1.3M USD | 1.12M USD |
| Operating expenses | 7.98M USD | 9.94M USD | 4.93M USD | 1.54M USD | 1.43M USD |
| Interest expense | 7.81K USD | 7.91K USD | 2.29M USD | 3.99M USD | 3.17M USD |
| Depreciation and amortization | 82.87K USD | 63.75K USD | 100.37K USD | 78.79K USD | 71.79K USD |
| Operating income | −7.76M USD | −9.71M USD | −5.15M USD | −1.75M USD | −1.12M USD |
| Net income | −7.37M USD | −7.95M USD | −3.77M USD | −6.18M USD | −4.25M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 20, 2026 | 1:4 | — | — |
Stock split | Feb 24, 2025 | 1:5 | — | — |
Stock split | Aug 12, 2024 | 1:12 | — | — |
Effective Jan 20, 2026
1:4
Effective Feb 24, 2025
1:5
Effective Aug 12, 2024
1:12
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
